Armata Pharmaceuticals Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $4.9M-5.2% YoYTTM through 30 Jun 2026
Net Income -$192.2MTTM through 30 Jun 2026
Free Cash Flow -$25.8MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| EBITDA Margin | -799.4% |
| Operating Margin | -646.4% |
| Net Margin | -3,544.0% |
Returns
79.5%ROE
Balance Sheet Health
Debt / Equity-1.10x
Current Ratio0.11x
Net Debt$338.1M
Cash & Equivalents$24M
Quality Metrics
Altman Z-Score-12.57
Piotroski F-Score2 / 9
FCF Margin-526.0%
Earnings-Beat Rate50.0%
Multi-Year Trend
Diluted EPS-$5.29TTMFY2025: $-4.80
Dividend
No dividend
Capital Allocation
Capex Intensity7.6%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Grant and Award Revenue | $4.9M | -5.2% | View detailsThe company continues to utilize non-dilutive grant awards to offset clinical development costs for its lead bacteriophage candidates. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.